Prospective, Multicenter Study Investigating Efficacy and Safety of Oral Rivaroxaban for the Prevention of Recurrent Venous Thromboembolism in Korean Patients With Cancers
Phase of Trial: Phase IV
Latest Information Update: 12 Dec 2017
Price : $35 *
At a glance
- Drugs Rivaroxaban (Primary)
- Indications Venous thromboembolism
- Focus Therapeutic Use
- 12 Dec 2017 Results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
- 06 Jan 2017 Status changed from active, no longer recruiting to completed.
- 21 Jun 2016 Planned End Date changed from 1 Feb 2017 to 1 Dec 2016.